The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
Open accessAbstract
Summary Background Hemophagocytic lymphohistiocytosis is a cytokine-driven inflammatory syndrome that is associated with substantial morbidity and mortality. Overall survival in adult patients with secondary haemophagocytic lymphohistiocytosis remains suboptimal, and novel therapeutic strategies are needed. The phosphorylation-dependent activation of the Janus family kinases JAK1 and JAK2 are hallmarks of the final common pathway in this disease. We therefore aimed to determine the activity and safety of ruxolitinib, a JAK inhibitor, in adults with secondary haemophagocytic lymphohistiocytosis. Methods We performed an open-label, single-centre, pilot study of ruxolitinib in adults with secondary haemophagocytic lymphohistiocytosis at the University of Michigan Rogel Cancer Center (Ann Arbor, MI, USA). We included patients aged 18 years or more who fulfilled at least five of the eight HLH-2004 criteria for hemophagocytic lymphohistiocytosis. Discontinuation of corticosteroids was not required for enrolment in this study. Patients received oral ruxolitinib (15 mg twice a day) on a continuous 28-day cycle, or until disease progression or unacceptable toxicity. The primary endpoint was overall survival at 2 months from the first dose of ruxolitinib. Secondary endpoints included the assessment of adverse events, response (defined as the assessment of all quantifiable signs and laboratory abnormalities included in the diagnostic criteria for haemophagocytic lymphohistiocytosis), and pharmacodynamic biomarkers. Analyses were done in all treated patients with available data. This study is registered with ClinicalTrials. gov, number NCT02400463, and is still recruiting. Findings As of Feb 7, 2019, five patients had been enrolled. The first patient was enrolled in February, 2016. No deaths were recorded, with a median follow-up of 490 days (IQR 190–1075). 2-month overall survival was 100% (95% CI 57–100). Regarding response, resolution of symptoms (either partial or complete) and disease-associated laboratory abnormalities was observed in all five patients. Cytopenias improved in all patients within the first week of treatment, leading to relatively rapid transfusion independence, discontinuation of corticosteroids, and hospital discharge. A single serious adverse event (ie, grade 4 febrile neutropenia) was reported. One patient discontinued treatment because of grade 2 extremity pain and no treatment-related deaths were observed. Improvements in inflammatory markers (eg, ferritin, soluble IL-2 receptor) and T cells and monocytes activation (ie, decreased STAT1 phosphorylation) were observed following treatment. Interpretation These preliminary data suggest that ruxolitinib is active, well tolerated, and manageable in the outpatient setting in patients with secondary haemophagocytic lymphohistiocytosis. Given the paucity of effective, non-myelosuppressive therapies, these preliminary findings have important therapeutic implications for patients with haemophagocytic lymphohistiocytosis and other cytokine-release syndromes and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Henter, J.-I. (2002) · Blood · doi:10.1182/blood-2002-01-0172 · Cited by 900
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Bergsten, E., Horne, A., Aricó, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., Ishii, E., Janka, G., Ladisch, S., Lehmberg, K., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788349 · Cited by 677
How I treat hemophagocytic lymphohistiocytosis in the adult patient
Schram, A. M., & Berliner, N. (2015) · Blood · doi:10.1182/blood-2015-01-551622 · Cited by 414
Cytokine Production Regulating Th1 and Th2 Cytokines in Hemophagocytic Lymphohistiocytosis
Osugi, Y., Hara, J., Tagawa, S., Takai, K., Hosoi, G., Matsuda, Y., Ohta, H., Fujisaki, H., Kobayashi, M., Sakata, N., et al. (1997) · Blood · doi:10.1182/blood.v89.11.4100 · Cited by 366
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 Patients
Rivière, S., Galicier, L., Coppo, P., Marzac, C., Aumont, C., Lambotte, O., & Fardet, L. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.04.034 · Cited by 324
Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis
Parikh, S. A., Kapoor, P., Letendre, L., Kumar, S., & Wolanskyj, A. P. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.12.012 · Cited by 323
Bracaglia, C., de Graaf, K., Pires Marafon, D., Guilhot, F., Ferlin, W., Prencipe, G., Caiello, I., Davì, S., Schulert, G., Ravelli, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209020 · Cited by 290
Cited by
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 285
Freyer, C. W., & Porter, D. L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.025 · Cited by 216
Metadata
- Authors
- Ahmed, A., Merrill, S. A., Alsawah, F., Bockenstedt, P., Campagnaro, E., Devata, S., Gitlin, S. D., Kaminski, M., Cusick, A., Phillips, T., Sood, S., Talpaz, M., Quiery, A., Boonstra, P. S., & Wilcox, R. A.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 6
- Issue
- 12
- Pages
- e630-e637
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2973341403
- Cited by
- 256
- References
- 28
- FWCI
- 26.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. https://app.cochat.ai/papers/10.1016/s2352-3026(19)30156-5
- The paper
- Ahmed, A., Merrill, S. A., Alsawah, F., Bockenstedt, P., Campagnaro, E., Devata, S., Gitlin, S. D., Kaminski, M., Cusick, A., Phillips, T., Sood, S., Talpaz, M., Quiery, A., Boonstra, P. S., & Wilcox, R. A. (2019). Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(19)30156-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.